Compare Caesars Entertainment Inc (CZR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Enveric Biosciences Inc — how do they compare? Caesars Entertainment Inc trades at $29.62 (market cap $6.06B), while Enveric Biosciences Inc trades at $1.56 (market cap $6.20M). The key difference: Caesars Entertainment Inc is far larger — about 977.4× Enveric Biosciences Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| CZR | ENVB | |
|---|---|---|
Market Cap | $6.06B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $17.40 |
52-Week Low | $18.14 | $1.27 |
Enterprise Value | $29.95B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $30.07, down 0.27% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a Q2 2026 net loss of $0.30 per share, missing estimates, while revenue of $3.0 billion topped expectations. Recent news highlights the pending $5.7 billion acquisition by Tilman Fertitta, which could reshape its ownership structure.
CZR offers value with low P/E and P/S ratios, but persistent net losses and high debt pose risks. The acquisition provides a potential exit near current levels, yet operational challenges and competitive pressures in the gaming sector warrant caution. Analyst consensus is mixed, with 30% buy ratings but 70% hold, reflecting uncertainty around profitability improvements.
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
